CYTX - Cytori Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Cytori Therapeutics, Inc.

3020 Callan Road
San Diego, CA 92121
United States
858-458-0900
http://www.cytori.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees65

Key Executives

NameTitlePayExercisedAge
Dr. Marc H. Hedrick M.D.596.25kN/A54
Mr. Tiago M. Girao344.56kN/A38
Mr. John D. Harris551.44kN/A48
Dr. John K. Fraser Ph.D.N/AN/A56
Mr. Russ HavranekN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The company also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s Sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer. It serves hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through direct sales force, third-party distributors, independent sales representatives, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California.

Corporate Governance

Cytori Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.